Semaglutide vs tirzepatide: what the evidence lets you compare

The short answer

You want to know which one works better. That's the question everyone arrives with, and it's the one the evidence handles worst.

Here's what can be said cleanly.

Ratings and trials from our research directory. Prices from our price market, checked 25 July 2026.

The real difference is receptors, not strength

Semaglutide activates one gut-hormone receptor. Tirzepatide activates two.

GIP and GLP-1 are both hormones your gut releases after eating. Both shape insulin, appetite, and how fast your stomach empties.²

Tirzepatide engages both pathways. Semaglutide engages the second one only.

People tend to hear "two receptors" as "stronger version," and that's the wrong frame. It's different pharmacology, which is why they're separate drugs rather than two doses of the same one.

Whether engaging both pathways produces a better outcome for a given person is exactly the question the evidence struggles to answer.

Why nobody can honestly rank them for you

This is the part that gets skipped everywhere else, so it's worth being precise.

The pivotal trials for each compound were largely run against placebo, not against each other.¹

That's completely standard for approval. It's also what makes ranking them hard.

Comparing a result from one trial against a result from another means comparing different people, different entry rules, different durations, and different ways of measuring.

Cross-trial comparison produces confident-sounding numbers that don't mean what they appear to. A difference between two trials can come from the drugs or from the populations, and from the outside you usually can't separate those.

Where a head-to-head trial does exist for a specific question, that's the evidence worth weighting. It's also a much narrower claim than the general ranking people want.

So the honest position:

What the evidence supports. Both reduce weight substantially versus placebo. Both are approved. Both have real outcome data beyond weight, in different domains: cardiovascular events for one, sleep apnea for the other.

What it doesn't support. A general statement that one is more effective or safer than the other for people in general.

We built the evidence-maturity framework around exactly this failure mode, where a striking number borrows authority it hasn't earned.

Where they differ most: how checkable they are

Both compounds are also sold by research vendors, and here the two diverge more sharply than anywhere in the clinical data.

Our testing ledger holds 117 published lab records.³ Thirty-three of them are tirzepatide. Two are semaglutide.

That asymmetry is the most practically useful thing on this page.

For tirzepatide there's enough published data to see a pattern. Identity confirmed throughout, purity between 99.39% and 99.97%, and 31 of 33 vials measuring over their labelled dose by a median of 13.1%.

For semaglutide there are two records. You can't characterise a supply from two samples, and an absence of published testing is not a clean result. It's an unknown.

So if verifiability is what you care about, the compounds aren't close, and the direction is the opposite of what the clinical evidence might suggest.

Details for each: tirzepatide's 33 records and semaglutide's two.

What price tells you here

Semaglutide runs $45.00 to $125.00 across two research vendors. Tirzepatide runs $34.00 to $180.00 across two.

Those look comparable and aren't, because they're package prices covering different vial sizes and quantities. Until you convert to cost per milligram at the same quantity, the numbers aren't in the same units.

Neither range says anything about quality. Both also sit apart from prescription pricing, which we keep in its own table for reasons we've written up.

How to actually decide

Not by picking a winner from a comparison table, including ours.

Both are approved and both are well evidenced. The choice turns on things no dataset holds.

What else you're being treated for. What you can tolerate. What your prescriber has seen work. And which approved use actually matches your situation.

What a page like this is good for is arriving informed rather than arriving persuaded. Know that the receptor difference is real, know that the ranking is weaker than it's presented, and know that one of the two is nearly impossible to verify outside a pharmacy.

Then have the conversation with someone qualified to weigh it.

Profiles with graded outcomes and sources: semaglutide and tirzepatide. New to all of this? Start at what peptides actually are.